AbbVievsKeros Therapeutics

ABBV and KROS stock compared: price, dividend, valuation and results, from SEC filings.

KROS

Keros Therapeutics, Inc.

$10.03

Value $198M

-2.62%
KROS's page

AbbVie (ABBV) has a market value of $521B and Keros Therapeutics (KROS) $198M. Over the last year, with dividends, ABBV moved +30.6% and KROS -41.9%. Dividend yield: ABBV 2.35%, KROS none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$521B

    KROS$198M

    ABBV is 2,633 times KROS

  • Revenue, 12 months

    ABBV$66.0B

    KROS$41M

    ABBV is 1,620 times KROS

  • Net income, 12 months

    ABBV$10.3B

    KROS-$62M

  • Operating margin

    ABBV32.2%

    KROS-179.8%

    211.9 points apart

  • ROIC

    ABBV25.7%

    KROS-15.8%

    41.5 points apart

  • P/E

    ABBV50.6

    KROS–

  • Dividend yield

    ABBV2.4%

    KROS0.0%

    2.4 points apart

  • 5-year return

    ABBV+201.4%

    KROS-83.7%

    285.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+201.4%

KROS-83.7%

010020030020222023202420252026
Returns by period
PeriodABBVWith dividendsKROSWith dividends
1 year since November 14, 2025+30.6%Price +26.8%-41.9%Price -41.9%
3 years since November 16, 2023+135.5%+33.0% a yearPrice +113.0%-68.1%-31.7% a yearPrice -68.1%
5 years since November 15, 2021+201.4%+24.7% a yearPrice +152.1%-83.7%-30.4% a yearPrice -83.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieKROSKeros Therapeutics

Valuation

ABBVKROS
Valuation
Price$294.55$10.03
Market value$521B$198M
Enterprise value (EV)$591B–
P/E50.6–
P/E, 5-year median57.0–
P/B–0.7
EV/EBIT27.8–
Free cash flow yield3.6%–

Results and growth

ABBVKROS
Results and growth
Revenue, 12 months$66.0B$41M
Net income, 12 months$10.3B-$62M
Free cash flow, 12 months$18.9B-$48M
Earnings per share, 12 months$5.81-$2.34
Revenue growth, year on year8.6%6,775.0%
Revenue growth a year, past+5.9%over 5 years–
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVKROS
Margins and returns on capital
Gross margin73.7%–
Operating margin32.2%-179.8%
Net margin15.7%-151.4%
ROIC25.7%-15.8%
ROE–-16.8%

Balance sheet

ABBVKROS
Balance sheet
Cash$10.8B$259M
Total debt$80.9B$15M
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVKROS
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%189.6%
Shareholder yield2.5%189.6%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or KROS

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Keros Therapeutics?

By market value, AbbVie ($521B) is about 2,633.5 times Keros Therapeutics ($198M), at today's prices.

How did ABBV and KROS stock do over the last 5 years?

Since November 15, 2021, ABBV's price moved +152.1% and KROS's -83.7%. With dividends: ABBV +201.4% (+24.7% a year), KROS -83.7% (-30.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or KROS?

The dividend yield at today's price is 2.35% for AbbVie and none for Keros Therapeutics. Over the last twelve months they paid $6.92 and – per share.

Which has the higher profit margins, AbbVie or Keros Therapeutics?

Over the last twelve months, the net margin was 15.7% for AbbVie and -151.4% for Keros Therapeutics, and the operating margin 32.2% and -179.8%. Revenue was $66.0B and $41M.

Which is the better investment, AbbVie or Keros Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.